Clinical Trial

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
Trial Details
NCT Number NCT06376045
Lead Sponsor Amgen
Conditions Asthma
Enrollment 317 participants
Start Date 2024-05-24
Primary Completion 2026-05-14 (estimated)
Study Completion 2026-06-22 (estimated)
Updated on ClinicalTrials.gov 2026-06-10